Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
about
Interferon for people with lamivudine-resistant chronic hepatitis B virus infectionAdefovir dipivoxil for adults with lamivudine-resistant chronic hepatitis B virus infectionBasal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutantsHepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudineA Practical Approach to Management of Chronic Hepatitis BHigh rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial.The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide AnalogsAntiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferonDirect acting antivirals for the treatment of chronic viral hepatitisCurrent and future antiviral drug therapies of hepatitis B chronic infectionSafety and efficacy of telbivudine for the treatment of chronic hepatitis BOutcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting listRecent data on treatment of chronic hepatitis B with nucleos(t)ide analogues.Current antiviral therapy for chronic hepatitis B.Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection.Antiviral therapy and resistance with hepatitis B virus infection.Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: a project of Kyushu University Liver Disease Study.Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B.Evaluation of the COBAS amplicor HBV monitor assay and comparison with the ultrasensitive HBV hybrid capture 2 assay for quantification of hepatitis B virus DNAHepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B.Management of viral hepatitis B.Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive.Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.Rapid and accurate genotyping of YMDD motif variants in the hepatitis B virus genome by an improved reverse dot blot method.Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.Current status of antiviral therapy for hepatitis BEvolving therapies for the treatment of chronic hepatitis B virus infection.Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.The role of entecavir in the treatment of chronic hepatitis B.Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy.Treatment of chronic hepatitis B: case selection and duration of therapy.Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.Probing rate of YMDD motif mutant in lamivudine treatment of Iranian patients with chronic hepatitis B virus infection.The cost-effectiveness of screening for chronic hepatitis B infection in the United States.Therapy of chronic hepatitis B: current challenges and opportunities.Clinical update: hepatitis B
P2860
Q24185973-E2C68771-D523-4AC1-B573-BE5CEBD3C0ABQ24187530-B13CFDCD-0A34-44F4-94CC-A057BA98FE03Q24563991-741CFED8-D262-4878-A6D0-6D57BB3B157BQ24806372-6DFD79E0-CF12-429B-8FCD-BADB05F63BDDQ24810145-9E82F8AF-18AC-4754-B6E9-7F45FB53FA42Q24814210-374523E5-E896-4BA2-84B4-EF75A4A4B61BQ26781795-48F81CA0-C46A-4225-B3AD-2B3371D15278Q26830435-C36024DA-A5A8-4AC7-8E1B-03331D99D347Q27022216-F9C9C962-A0C8-4B25-AE15-6B687071430FQ28084820-90AD2174-A1AA-4D0F-9B05-23EB2B1C363EQ28972486-AAAECCA7-CB78-4380-ABA3-981E3CC12177Q30440211-CD9CC846-91C6-4F4E-9FD6-F6FC36DE9515Q33492413-359740FA-FBBE-46F5-B897-F787BF381D12Q33631693-CC773468-E8E1-4B9E-8CC4-010AC8201D7CQ33631739-948B792F-A72D-428F-AB0E-C18A6997BA53Q33787531-7336BE88-A495-43F1-9C13-7BFA985B5306Q33788309-E8E22188-CC1F-4E20-AAFB-89ABD45670F3Q33819124-00BD2BB4-131C-47D1-8B9F-90D6F11E93B2Q33825842-1852D99B-95A8-4223-BDFB-F716092A3F6AQ33950133-53DFFAAB-ECDC-44F8-82F8-F607E773597CQ33959006-DF6914B7-A83F-4BD1-A3FA-C6E36E8E9CF3Q34017787-EF28DBD3-7E87-42FD-99BF-11496A20CAF2Q34045308-36E93F5F-841F-4655-AFC7-4E1AF7D76A9AQ34137291-D0276366-61A8-4067-AC0E-CF13226FA614Q34143643-3B0AA8B9-6709-4E1C-9A73-CECD5D3D17EFQ34382067-DECF5782-5997-49D6-A7EF-FCED66099EFEQ34408879-FDBD57F1-91F2-4E9B-A067-17A65E0CF23DQ34519117-AC00F79A-1D7E-4D11-989A-94E49457757FQ34584406-05BAD46F-D5AA-41A2-BFBC-7556B52CCE06Q34592640-69E9ECB0-2536-401E-BFAC-EFF2001AB409Q34594403-9E8D6A73-8614-4080-9669-C8ACC526CB34Q34599741-8C06CFCB-A409-4F7E-962B-7CD5D82A6AB4Q34619363-847FEEB7-71C7-487D-940C-2581202730A0Q34674838-49FABA7B-4A2A-4A1C-A6DF-113C60BF6161Q34700034-3FCE2C30-2A15-43C6-BDE6-CA896ACD635AQ34809263-3331C152-BCF9-4C2A-871F-86DE7464A77EQ34862728-327DBD77-7D21-4AA2-868B-62ECBFB36048Q34990604-08150F79-57C5-438A-BA3B-FF65F29E5C1CQ34996613-8332CC91-CA88-4C6D-8430-77BBF5E6E16AQ34996687-47895E82-DB29-46AA-AF76-69B547625FBC
P2860
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Extended lamivudine treatment ...... ults after 3 years of therapy.
@en
Extended lamivudine treatment ...... ults after 3 years of therapy.
@nl
type
label
Extended lamivudine treatment ...... ults after 3 years of therapy.
@en
Extended lamivudine treatment ...... ults after 3 years of therapy.
@nl
prefLabel
Extended lamivudine treatment ...... ults after 3 years of therapy.
@en
Extended lamivudine treatment ...... ults after 3 years of therapy.
@nl
P2093
P356
P1433
P1476
Extended lamivudine treatment ...... ults after 3 years of therapy.
@en
P2093
Asia Hepatitis Lamivudine Study Group
L D Condreay
P304
P356
10.1053/JHEP.2001.25084
P407
P577
2001-06-01T00:00:00Z